Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Kidney Stone Management Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global market size for kidney stone management reached a value of USD 1.80 billion in 2023. The market is expected to grow at a CAGR of 5.20% between 2024-2032 and attain a value of USD 2.84 billion by 2032. Increasing prevalence of kidney stones, technological advancements in treatment options, and rising awareness about kidney health a ...

Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillationMARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and drivers outside of the pulmonary veins that ...

纪要涉及的行业或者公司: - 心血管医疗器械行业 - 波士顿科学公司(Boston Scientific Corporation) 纪要提到的核心观点和论据: 1. 波士顿科学公司的心血管业务整体表现良好,2024年前三季度在美国和国际市场均实现两位数增长。[6] 2. 公司的FARAVIEW软件模块和FARAWAVE导管获得FDA批准,在多家医院成功应用,提高了手术效率。[8,9] 3. ACURATE TAVR系统在ACURATE IDE临床试验中未达到主要终点,但进一步分析发现,当ACURATE valve扩张良好时,临床结果与对照组相当。[29-33] 4. 公司正在积极与FDA沟通,寻求ACURATE TAVR系统在美国的监管路径。[53-54] 5. 公司在其他产品线如SENTINEL、AGENT和WATCHMAN FLX Pro也取得了积极的临床数据。[40-43] 6. 公司将继续投资于完整的结构性心脏产品线,包括三尖瓣和二尖瓣产品。[55-57] 其他重要但可能被忽略的内容: 1. ACURATE IDE临床试验在COVID-19疫情期间进行,受到了一些不利影响,如患者入组速度缓慢、设备供应受限、操作者经验不足等。[27-28] 2. 公司正在积极开发下一代ACURATE Prime TAVR系统,并计划在未来发布相关临床数据。[39] 3. 公司在机械循环辅助设备领域也有投资,计划在2025年底前启动美国IDE研究。[17]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?The Zac ...

文章核心观点 - 波士顿科学公司(Boston Scientific)在国际市场上正在获得牵引力,新的监管批准和收购有助于其长期增长 [1] - 公司在欧洲、中东和非洲(EMEA)地区的销售增长强劲,得益于其多元化产品组合、新产品推出和出色的商业执行能力 [2] - 公司的内窥镜业务在全球范围内需求强劲,特别是AXIOS和Exalt D产品的市场份额增长 [3] - 公司近期的战略收购为其带来了大量具有巨大潜力的新产品,有望带动未来收入增长 [4][5] 公司概况 - 公司在国际市场的收入占比达41% [2] - 公司在EMEA地区的销售增长14.3%,主要得益于电生理、复杂PCI和结构性心脏业务的强劲表现 [2] - 公司最近完成了收购Silk Road Medical和Axonics的交易,有助于拓展其在血管医疗和泌尿科领域的业务 [5] 行业趋势 - 宏观经济环境的挑战,如地缘政治压力、供应链和劳动力市场的中断,给公司的经营带来压力 [7] - 成本上升导致毛利率和营业利润率下降 [7] - 汇率波动对公司收入产生负面影响,2023年约80个基点,2024年Q3约10个基点 [8]

市场规模与增长 - 2024年预计心脏病学市场规模为380亿美元，预计到2027年将增长约8%[9] - 心脏介入治疗（ICTx）在2024年市场规模为86亿美元，预计将实现高双位数增长[9] - WATCHMAN设备在2024年市场规模为67亿美元，预计将实现高双位数增长[9] - 2024年全球心脏病学增长率为23%，美国市场增长12%，国际市场增长19%[12] - AGENT药物涂层气球在2024年市场规模为13亿美元，预计将实现低双位数增长[16] 产品与技术研发 - ACURATE Prime主动脉瓣系统于2024年10月17日在欧洲推出，具有20.5mm至29mm的扩展治疗范围[33] - 2024年心脏病学产品的FDA批准和上市包括WATCHMAN TruSteer和FARAPULSE脉冲场消融系统[13] - ACURATE neo2的主要终点在1年内未达到非劣效性，死亡、卒中或再住院率为6.63%[29] - AGENT药物涂层气球的IVUS使用率为96%，显示出在复杂病例中的广泛应用[18] 财务表现 - 2024年心脏病学的非GAAP财务措施显示出强劲的运营增长，排除外汇波动的影响[7] - 心脏病学净销售增长：介入心脏病治疗增长10%，WATCHMAN增长19%，心脏节律管理增长3%，电生理增长124%[37] - 美国地区心脏病学净销售增长27%，国际地区增长16%[38] - 介入心脏病治疗的运营基础增长为12%[37] - WATCHMAN的运营基础增长为19%[37] - 电生理的运营基础增长为126%[37] 临床数据与患者招募 - 在美国共招募了1,833名患者[34] - TAVR与SENTINEL脑保护系统相关的所有中风/致残性中风发生率显著降低，且患者在72小时内出院的可能性更高[34] - AGENT DCB亚组分析显示，AGENT药物涂层气球在不同患者群体中均表现出一致的益处，包括少数族裔与白人、大小血管及男性与女性[34] - 首500名患者的六个月主要安全性终点达成，包括全因死亡率、所有中风、系统性栓塞和重大出血[35] - FLX Pro LAAC设备在六个月内未出现与DRT相关的不良事件[35]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2695240 (State or other jurisdiction of incorporation ...

The Seeking Alpha analysts who have covered Boston Scientific Corporation (NYSE: BSX ) since the beginning of this year have concerns about the company. The last nine ratings, since January 10, 2024 have all been Holds. To find a BuyRobert F. Abbott has been investing his family’s accounts since 1995, and in 2010 added options, mainly covered calls and collars with long stocks. He is a freelance writer, and his projects include a website that provides information for new and intermediate-level mutual fund i ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth S ...

U.S. stock markets have been witnessing an impressive rally since the beginning of 2023, barring some minor hurdles. Wall Street’s bull run has got an added boost this year, to the surprise of a large section of financial pandits, who indiscriminately warned of overvaluation. Year to date, the three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — have advanced 11.7%, 22.6%, and 26%, respectively. Consequently, various S&P 500 stocks have climbed this year. Here we have selected five S& ...